Illustration: Annelise Capossela/Axios
Redi Health, a medication adherence and patient engagement tech platform, raised a $14 million Series B, CEO Luke Buchanan tells Axios exclusively.
Why it matters: Early support with specialty drugs can address the 70% non-adherence rate that causes hundreds billions of dollars in losses.
